ATX-MS-1467 is being developed by Apitope Technology.
Current phase of trial: Phase 2
Type of MS: Relapsing MS.
How does ATX-MS-1467 work?
In MS, the body’s own immune cells mistakenly attack the myelin that surrounds nerve cell fibres. ATX-MS-1467 aims to reduce this attack by ‘switching off’ (or desensitising) the immune response to myelin.
This is achieved by giving somebody parts that make up myelin, which are targeted by the immune system in MS. The theory is that by gradually increasing the dose the immune system to ‘get used to’ myelin and stop attacking it.
This approach is sometimes referred to as immune ‘desensitisation’.
How is ATX-MS-1467 taken?
ATX-MS-1467 is injected under the skin once every two weeks.
Latest ATX-MS-1467 research
Phase 2 clinical trial
Initial results were announced in February 2017. ATX-MS-1467 significantly reduced new active lesions on MRI scans. As this was a small study involved 19 people with relapsing MS, everyone on the trial took ATX-MS-1467.
Those taking part took increasing doses of ATX-MS-1467 for four weeks, and then maintained the highest dose for 16 weeks. While these results are encouraging, they need to fully analysed and published in a scientific journal.
A phase 1 study involved 43 people with relapsing MS, who received increasing doses of ATX-MS-1467 every two weeks. Researchers reported that ATX-MS-1467 reduced the number of active lesions (as seen on an MRI scan) when injected under the skin.
What are the side effects of ATX-MS-1467?
ATX-MS-1467 has been reported to be safe and well tolerated in the small, phase 1 and 2 studies.
How does ATX-MS-1467 compare with current therapies?
ATX-MS-1467 hasn’t yet been directly compared with other MS therapies.
When is ATX-MS-1467 likely to become available?
ATX-MS-1467 is being tested in phase 2 trials. If the results are positive, this should encourage larger, phase 3 trials. This process is likely to take several years – we will keep you updated on the progress of ATX-MS-1467.